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A review of 172 patients with squamous cell cancer of the vulva 
treated at the University of Michigan Medical Center from 1975 
1989 was performed to compare the 1988 FIG0 Staging System 
to the 1970 FIG0 Staging System. The stage distribution ac- 
cording to the 1970 FIG0 Staging System was stage I, 65; stage 
II, 44, stage III, SO; and stage IV, 13. The cumulative S-year 
survival under the old system was stage I, 94%; stage II, 91%; 
stage III, 36%; and stage IV, 26%. The distribution changed 
under the 1988 FIG0 system to stage I, 58; stage II, 36; stage 
III, 49; stage IVA, 16; and stage IVB, 13. The cumulative survival 
also changed to stage I, 94%; stage II, 89%; stage III, 71%; stage 
IVA, 19%; and stage IVB, 8%. The new FIG0 stage distribution 
shifted for the worse due to the influence of positive lymph nodes 
found at the time of surgery. The survival was then analyzed for 
death from all causes. This was markedly decreased when com- 
pared to the cumulative corrected survival. This relates to the 
high number of other primary malignancies and the age of the 
patients. Among these 172 patients, other primary malignancies 
included squamous cell cancer of the cervix (ll), squamous cell 
cancer of the vagina (2), endometrial cancer (3), squamous cell 
cancer of the lung (2), colon cancer (3), and others (6). An 
additional 5 patients died from myocardial infarction within 2 
years of diagnosis. The new 1988 FIG0 Staging System provides 
for better discrimination of survival between stages than the 1970 
FIG0 Staging System. 0 1992 Academic press, 1~. 
INTRODUCTION 
Squamous cell carcinoma of the vulva remains localized 
for extended periods of time and spreads in an orderly 
fashion. Various risk factors have been evaluated for this 
disease and most authors agree that the lymph node status 
appears to be a critical determinant of survival. Prior to 
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1 To whom reprint requests should be addressed at Department of 
Obstetrics & Gynecology, Northeastern Ohio Universities College of 
Medicine, 400 Wabash Avenue-ACC, Akron, OH 44307. 
1988 the staging of vulvar cancer was based on the ex- 
aminer’s clinical evaluation of the lymph node status and 
the tumor location [ 11. Thus, enlarged lymph nodes which 
were clinically suspicious or clinically positive influenced 
the stage regardless of the actual disease status. Alter- 
natively, when lymph nodes were clinically negative, if 
they were found to be positive at the time of groin node 
dissection it would not change the final stage. Freidrich 
and DiPauloa in 1977 suggested that the staging system 
be changed to incorporate this information [2]. Over the 
last 20 years, radical vulvectomy, bilateral groin node 
dissection, with or without pelvic lymph node dissection, 
has become the standard therapy for this disease. Thus, 
most patients undergo surgery and the lymph node status 
is known. The FIG0 staging system, therefore, was re- 
cently changed to a surgical staging system which accounts 
for the actual pathologic status of the lymph nodes [3]. 
The other change incorporated into the new staging sys- 
tem was the elimination of perineal involvement which 
previously classified the patient as stage III. 
This study was undertaken to compare the new surgical 
staging system to the old clinical staging system and de- 
termine if this new staging system provided a better pre- 
dictor of survival between stages. An analysis was also 
done to evaluate the probability of dying from all causes 
during this time period. 
MATERIALS AND METHODS 
A review of all patients with squamous cell carcinoma 
of the vulva treated at the University of Michigan during 
the time period 19751989 was undertaken. All records 
were reviewed including the clinical charts, pathology re- 
ports, operative notes, and gynecologic tumor conference 
notes. All patients during this time period had been staged 
according to the 1970 FIG0 TNM System. A separate 
review of these data was then done to stage patients 
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COMPARISON OF STAGING SYSTEMS FOR VULVAR CARCINOMA 
TABLE 1 
Changes in FIG0 Stage when Comparing the 1970 
Distribution by Stage to the 1988 Staging System 
FIG0 1988 
FIG0 1970 
Stage Stage Stage Stage Stage 
Stage No. I II III IVA IVB 
Stage 1 65 58 7 
Stage II 44 - 34 10 
Stage III 50 2 30 11 7 
Stage IV 13 - 2 5 6 
Total 58 36 49 16 13 
according to the 1988 FIG0 Staging System. Survival 
analysis was performed using a Kaplan-Meier Analysis 
[4]. The cumulative survival analyzes the probability of 
dying only from cancer, deleting patients as censored data 
when they die from other causes. The absolute survival 
analysis includes death from all causes. Statistical analysis 
was performed by the Northeastern Ohio University’s 
College of Medicine, Biostatistics Department. A detailed 
analysis of separate risk factors which influenced survival 
utilizing the 1970 FIG0 Staging System has been previ- 
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FIG. 1. Survival according to stage of disease utilizing the 1970 
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FIG. 2. Survival according to stage of disease utilizing the 1988 
FIG0 Surgical Staging System. 
RESULTS 
A total of 172 patients were treated for squamous cell 
carcinoma of the vulva during this time period. The dis- 
tribution by the 1970 FIG0 Staging System is compared 
to the 1988 FIG0 Staging System in Table 1. A total of 
7 patients with stage I disease were changed to stage III 
disease. These patients were staged higher under the new 
system due to the presence of positive unilateral lymph 
nodes. Ten patients with stage II disease were changed 
to Stage III under the new system. Again, all due to 
positive lymph nodes. There were no patients with stage 
I or II disease who changed their stage to IVA or IVB. 
The greatest change occurred in stage III disease where 
50 patients were stage III in the 1970 system and only 30 
of these 50 remained as stage III in the new system. 
Upstaging occurred for 18 patients, 11 to stage IVA and 
7 to stage IVB. The 7 upstaged to IVB were all due to 
positive pelvic nodes. Two patients were downstaged to 
stage II disease. One patient had clinically positive nodes 
which on pathologic examination were negative. The 
other patient had a perineal lesion. Among the 13 patients 
with old FIG0 stage IV disease, 2 were downstaged to 
stage III and the other 11 were split evenly between stage 
IVA and IVB. 
The cumulative corrected 5-year survival for all patients 
was 71% with a cumulative 2-year survival of 75%. Sur- 
vival curves constructed for the 1970 FIG0 system and 
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FIG. 3. Survival when accounting for death from all causes ac- 
cording to 1988 FIG0 stage. 
the 1988 FIG0 system are presented in Figs. 1 and 2. 
Among patients with stages I and II disease, the cumu- 
lative 5-year survival changed very little. The 5-year sur- 
vival in stage I remained the same at 94% while the 
cumulative 5-year survival for stage II changed from 91 
to 89% in the new FIG0 system. The greatest change 
occurred among patients with stage III disease. Under 
the old FIG0 staging system in which stage III could 
include patients with pathologically proven bilateral pos- 
itive groin nodes and positive pelvic nodes, the cumulative 
5-year survival was 36%. Under the new system, where 
only patients with unilateral positive groin nodes are in- 
cluded, the 5-year survival was 71%. Stage IV disease is 
now substaged into stages IVA, and IVB. Utilizing the 
new system there is a difference in cumulative survival 
of 19% for stage IVA versus 8% for stage IVB. As ex- 
pected, the difference in survival between all the stages 
is significant (P < 0.0001). 
A separate absolute survival analysis was performed 
where all causes of death were included. The absolute 5- 
year survival was markedly decreased when compared to 
the cumulative corrected survival which only accounted 
for patients who died from vulvar cancer. The absolute 
5-year survival for all patients was only 62%. Patients 
with stage I disease had an absolute survival of 90% and 
this dropped to 19 and 0% for stages IVA and IVB, 
respectively (Fig. 3). The lower absolute survival was 
influenced by the older age of the patients, other primary 
malignancies, and cardiac disease. The mean age of the 
patient population was 66 years with a range of 21 to 101 
years. Second primary malignancies were frequent and 
the sites are listed in Table 2. Eight of these patients died 
from cancer other than vulvar cancer. Myocardial infarc- 
tion within 2 years of the time of diagnosis was the cause 
of death in five patients. 
DISCUSSION 
The 1988 FIG0 Staging System attempts to incorporate 
the known prognostic variables for squamous cell carci- 
noma of the vulva. The greatest change in staging has 
been from a clinical to a pathologic system including the 
lymph node status. The new staging system utilizes the 
known prognostic variables of positive unilateral (stage 
III) versus positive bilateral groin lymph nodes (stage 
IVA), versus positive pelvic lymph nodes (stage IVB). 
Under the old FIG0 system there is little survival dif- 
ference between patients with stage I or II disease and 
between patients with stage III or IV disease. When uti- 
lizing the new system there still remains little difference 
in survival between stages I and II. This is probably due 
to a number of factors. Under the old system, lymph 
nodes which were clinically negative but pathologically 
positive usually contained only microscopic disease and 
thus were less likely to significantly influence the survival. 
Under the new system, the only discrimination between 
stage I and stage II disease is the size of the primary 
tumor, less than 2 cm or greater than 2 cm. This difference 
in size alone does not provide a great difference in 
survival. 
In the old FIG0 system there is a marked drop in 
survival for stages III and IV disease. Under the new 
FIG0 system there are more pronounced survival dif- 
ferences between stages III, IVA, and IVB. Stage III 
disease carries a much better prognosis in the new system 
and this is almost certainly related to the presence of 
bilateral positive groin nodes now being classified as stage 
IVA disease. These results are similar to those reported 
TABLE 2 
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by Homesley where survival was 74% for stage III uti- 
lizing the new staging system and decreased to 31% for 
all patients with stage IV disease [6]. 
Because there is a difference in survival of 50% be- 
tween stages III and IVA, other known prognostic risk 
factors will still be needed to predict which patients will 
survive. One predictive feature that is lost in the new 
staging system is the clinical impression of lymph node 
status. Iversen reported 100 patients with positive nodes. 
Those with clinically negative nodes had a 56% survival 
compared to 34% when nodes were clinically positive [7]. 
The cumulative disease-free survival is a method of 
analyzing treatment results and reporting only those pa- 
tients who die from tumor-related deaths. Patients who 
die from other causes are removed as censored data but 
not as a death from disease. This provides an accurate 
survival picture as it relates to the cancer treatment but 
may not reflect the actual survival of the patient popu- 
lation. Because this patient population is elderly, the ab- 
solute survival provides an indicator of how many are 
alive regardless of the cause of death. It appears that in 
vulvar cancer the actual or absolute survival is markedly 
different from the cumulative disease-free survival. In our 
report a number of patients died from other causes. The 
population is elderly and almost 3% died from myocardial 
infarction. There also was a large number of secondary 
malignancies. Importantly, there was a high number of 
other squamous cell malignancies, especially involving the 
cervix, the vagina, and the lung. This finding concurs with 
the hypothesis of the field effect of a carcinogen involving 
the cervix, vagina, and vulva. 
The new FIG0 Staging System appears to be a better 
discriminator in determining survival from disease. The 
absolute survival appears to be markedly decreased when 
compared to the cumulative disease-free survival. The 
treatment for vulvar cancer includes radical surgery which 
often can be debilitating; therefore, a vigilant search 
should be done for other malignancies which may influ- 
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